Patent Issued for Pyrimidine compounds as JAK kinase inhibitors (USPTO 11110095)

摘要

2021 SEP 27 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Beausoleil, Anne-Marie (Redwood City, CA, US), Fatheree, Paul R. (San Francisco, CA, US), Fleury, Melissa (Brisbane, CA, US), Huang, Xiaojun (Sunnyvale, CA, US), Hudson, Ryan (San Jose, CA, US), Kozak, Jennifer (Pacifica, CA, US), Podesto, Dante D. (Modesto, CA, US), filed on October 18, 2019, was published online on September 7, 2021. The assignee for this patent, patent number 11110095, is Theravance Biopharma R&D IP LLC (South San Francisco, California, United States). Reporters obtained the following quote from the background information supplied by the inventors: "Field of the Invention "The invention is directed to pyrimidine compounds useful as JAK kinase inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory diseases, and processes and intermediates useful for preparing such compounds.